HANSOH PHARMA: B7-H3 targeted antibody-drug conjugate HS-20093 received FDA breakthrough therapy designation for relapsed or refractory osteosarcoma in later lines of treatment
I'm PortAI, I can summarize articles.
HANSOH PHARMA announced that its B7-H3 targeted antibody-drug conjugate HS-20093 has received Breakthrough Therapy designation from the U.S. FDA for patients with relapsed or refractory osteosarcoma. The drug is covalently linked with a fully human anti-B7-H3 monoclonal antibody and a topoisomerase inhibitor payload, and is currently undergoing multiple clinical studies in China, covering various solid tumors including lung cancer, sarcoma, and head and neck cancer
Log in to access the full 0 words article for free
Due to copyright restrictions, please log in to view.
Thank you for supporting legitimate content.
Source: Zhitong The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments